Solarvest to Focus on in-House Product Expansion

- May 27th, 2021

Solarvest BioEnergy Inc. is pleased to announce that as part of its operational  expansion program, the Company has added key personnel.  These positions will be required as production volumes increase to allow the company more control over quality control and scheduling, and increase the profitability of the finished product. Additionally, the Company will be better able to facilitate the development and scale up …

(TheNewswire)

Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS), is pleased to announce that as part of its operational  expansion program, the Company has added key personnel.  These positions will be required as production volumes increase to allow the company more control over quality control and scheduling, and increase the profitability of the finished product. Additionally, the Company will be better able to facilitate the development and scale up of new products using its proprietary processes while ensuring organic and cGMP compliance

The following three team leaders have been added to the Company’s operations:

First, the Company has hired a Production Team Leader who has spent the last 7 years with Novartis/Eli Lilly focusing on technology transfer and scale-up of fermentation processes, from research and development scale to commercial manufacturing scale, with new automated fermentation systems. His expertise will be important as the company expands its contract manufacturing and commissions in-house production.

Secondly, joining the Company is a Regulatory Affairs/QC Manager who has expertise in internal and external quality control audit programs, and will conduct quality management and technical audits against the ISO/IEC 17025 standard and the ISO 9001 standard. Hosting external audits for the SCC, Canadian Food Inspection Agency (CFIA), Public Health Agency of Canada (PHAC) and clients. Her regulatory experience will help the Company open new markets while her seven years of experience with the Atlantic Veterinary College will have immediate applications with the recently announced animal health product development program.

Finally, we welcome a Product Development Scientist who has experience in the nutraceutical/food processing business both with internal production processes and maintained supplier(s) approval program.  She will be supporting our “white label” 3 rd . party customers and their development teams as we design new value added products using our proprietary EU and USDA certified organic Omega-3 powder.

Gerri Greenham, CEO commented, “As the market for our products continues to grow, these experienced employees will complement our fermentation and production operations in our facility in Summerville, PEI and will provide additional operational expertise for future expansion while maintaining the Company’s commitment to quality control.  This facility has been built to accommodate large scale fermentation and will be one of only a few large scale organically certified fermentation suites in the world.  Prince Edward Island has a thriving Bio-Science sector with extremely qualified professionals running installations for many  bio-pharmaceutical/pharmaceutical companies.“

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of B MP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the terms of the Offering, the completion of the Offering and the expected use of the net proceeds received by the Company. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: general business, economic, competitive, geopolitical and social uncertainties; and regulatory risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement. The Company does not undertake to update any forward-looking information, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of Solarvest have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “ U.S. persons ” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Copyright (c) 2021 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply